NeuroOne Medical Tech 주식 (NASDAQ: NMTC)

에 대한 최신 뉴스 NeuroOne Medical Tech (NASDAQ:NMTC) 주식

NeuroOne Medical Tech

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NMTC

SGMO

금요일(4일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다. 금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

금요일 주목해야 할 주식: 아메리칸 셰어드, 게스, 뉴로원 메디컬, 시뮬레이션스 및 상가모 테라퓨틱스

NeuroOne Medical Technologies Corporation - Common Stock

NeuroOne Medical Technologies Corp

Electra Battery Materials Corporation (NASDAQ:<a href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>, TSXV:<a href="https://www.benzinga.com/stock/ELBM#TSXV">ELBM</a>) ("Electra" or the "Company") announces the launch of an early works program at its cobalt refinery north of Toronto, reaffirming the Company's commitment to onshoring North America's critical minerals processing and building a resilient, domestic battery materials supply chain.
The early works program encompasses targeted site-level activities designed to prepare for the restart of full-scale construction. The initiative reflects growing momentum around the project, supported by strategic funding from both the U.S. and Canadian governments. The work, budgeted at approximately C$750,000, is particularly focused on advancing the solvent extraction facility.

ELBM

Electra Battery Materials Launches Early Works Program At Cobalt Refinery North Of Toronto, Reaffirming The Co's Commitment To Onshoring North America's Critical Minerals Processing And Building A Resilient, Domestic Battery Materials Supply Chain

Today, Triumph Group, Inc. (TRIUMPH) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) and Divergent Technologies, Inc. (Divergent) announced a partnership to qualify multiple critical manned aircraft components manufactured with the Divergent Adaptive Production System (DAPS&#x2122;), marking a significant milestone in bringing advanced digital manufacturing technologies into production for high-performance aerospace applications.
The components, which play a critical role in flight safety, are undergoing rigorous testing and validation protocols. Each will be certified by an empowered regulatory authority for use on a high-performance aircraft, validating the growing adoption of additive manufacturing for mission-critical aerospace applications. The speed that the partnership has demonstrated in requalifying the components further highlights the strength of Divergent's capabilities to resolve supply chain constraints posed by legacy manufacturing methods such as casting.
TRIUMPH's gearbox component design, engineering, prototyping, and qualification process leveraged Divergent's fully digital toolchain, ultimately delivering first-time-right, production-fidelity structures for testing and enabling a seamless transition to production. DAPS&#x2122; is an end-to-end engineering design and manufacturing system leveraging AI-driven design, industrial-rate additive manufacturing, and universal robotic assembly to deliver structures that are faster to develop, higher performance, and lower cost than their conventionally designed and manufactured alternatives. TRIUMPH is identifying applications across multiple product lines where TGI and Divergent can partner and implement these 4th gen manufacturing processes.

Triumph Group And Divergent Technologies Partner To Qualify Critical Manned Aircraft Components Using Advanced Digital Manufacturing And Additive Production System

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S.
The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. With the iLet, people living with diabetes can achieve excellent clinical outcomes without the burden of carb counting&#x2A; or manual insulin correction calculations. The system currently supports Abbott's FreeStyle Libre&#xAE; 3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market.

Biotech

General

BBNX

Beta Bionics To Integrate iLet Bionic Pancreas With Abbott's Upcoming Dual Glucose-Ketone Sensor, Advancing Automated Insulin Delivery In The U.S.

Descartes Systems Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DSG#TSX">DSG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired PackageRoute, a leading provider of final-mile carrier solutions.
Based in the US, PackageRoute's mission is to simplify and optimize the daily operations of final-mile carriers. The company offers a mobile and web-based platform that provides real-time visibility into package deliveries, route optimization, and fleet management. PackageRoute's software integrates seamlessly with pickup and delivery data, enabling contractors and drivers to make better-informed decisions and operate more efficiently. &nbsp;&nbsp;
Descartes GroundCloud helps ensure seamless operations, end-to-end visibility, and standards of safety and compliance are met, including helping final-mile carriers comply with the various safety mandates of large transportation brands.
PackageRoute is headquartered in Sammamish, WA. Descartes acquired PackageRoute for approximately US $2 million, satisfied from cash on hand.

DSGX

TSX:DSG

Descartes Systems Group Acquires PackageRoute For ~$2M, Satisfied From Cash On Hand

The Los Angeles Lakers are reportedly on the verge of being sold for a blockbuster price. While the absolute returns on the investment sound incredible, analysts on X are quick to point out that it&#8217;s not nearly as impressive as it seems.
What Happened: On Wednesday, it was reported that the Buss family, longtime owners of the Los Angeles Lakers, is preparing to sell the franchise for a staggering $10 billion. That's a jaw-dropping leap from the $68 million the late Jerry Buss paid for it in 1979.
This represents a monumental 15,284% return. But viewed through the lens of long-term compounding, some analysts say that it's far from exceptional.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46012786/chamath-palihapitiya-asks-if-he-should-launch-another-spac-70-say-no-users-warn-of-past-failures-no-crying-in-the-casino">Chamath Palihapitiya Asks If He Should Launch Another SPAC—70% Say No, Users Warn of Past Failures: &#8216;No Crying In The Casino!&#8217;</a>
Users point out that adjusted for inflation, Buss' 1979 investment is equivalent to about $280 million in today's dollars. That makes the real multiple closer to 36x. 
Over 45 years, this equates to a compounded annual return of just under 10.5%, roughly in line with the S&amp;P 500's historical average. And that's before taxes, reinvestment risks and the operational headaches of running an NBA franchise.
Popular X user, Trung Phan, compares the investment relative to the performance of the S&amp;P 500 over the years, concluding that a $68 million investment in the S&amp;P 500 in 1979 would now be worth $13 billion. &#8220;So the Buss family underperformed by $3B,&#8221; he says.
However, Phan acknowledges that the &#8220;infinite cultural clout&#8221; that this investment brought the family might be well worth it, referring to the Lakers&#8217; 11 Championship wins over the years, alongside the remarkable brand and pop-culture legacy that&#8217;s been cemented over the years.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Jerry Buss bought the LA Lakers, LA Kings and The Forum for $68m in 1979. The Buss family just sold a majority stake at a $10B valuation (Buss sold LA Kings in 1988 and The Forum in 2000). Since 1979, a $68m investment in S&amp;P 500 is now worth $13B. So, Buss family… <a href="https://t.co/Nq9wHnqpfU">pic.twitter.com/Nq9wHnqpfU</a>
&mdash; Trung Phan (@TrungTPhan) <a href="https://twitter.com/TrungTPhan/status/1935458198707913173?ref_src=twsrc%5Etfw">June 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: While passive investing with an S&amp;P 500 index fund, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), would have outperformed one of the most popular NBA teams, here are a few other assets that have fared much better during this period. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Asset</td>
<td class="has-text-align-center" data-align="center">46-Year CAGR</td>
<td class="has-text-align-center" data-align="center">Absolute Returns</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Los Angeles Lakers</td>
<td class="has-text-align-center" data-align="center">11.46%</td>
<td class="has-text-align-center" data-align="center">15,284%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)</td>
<td class="has-text-align-center" data-align="center">9.39%</td>
<td class="has-text-align-center" data-align="center">5,446%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Fidelity NASDAQ Composite Index ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEQ#NASDAQ">ONEQ</a>) 
<div class="nwVKo" style="align-items: center; display: flex; color: rgb(31, 31, 31); font-family: Arial, sans-serif; font-size: 14px; text-align: left; white-space-collapse: collapse;">
<div class="loJjTe" style="display: flex; min-width: 0px; gap: 8px;"></div>
</div>
</td>
<td class="has-text-align-center" data-align="center">11.74%</td>
<td class="has-text-align-center" data-align="center">16,467%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Gold Spot Price</td>
<td class="has-text-align-center" data-align="center">6.05%</td>
<td class="has-text-align-center" data-align="center">1,392%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) </td>
<td class="has-text-align-center" data-align="center">18.17%</td>
<td class="has-text-align-center" data-align="center">216,723%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">It&#8217;s worth noting that ETFs that tracked index funds did not exist in 1979, and the returns showcased exclude dividends for each of the assets listed above.</figcaption></figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/tax/25/06/46012776/brace-for-higher-healthcare-premiums-in-2026-as-insurers-blame-trumps-tariffs-in-filings-to-regulators-report">Brace For Higher Healthcare Premiums In 2026 As Insurers Blame Trump&#8217;s Tariffs In Filings To Regulators: Report</a></li>
</ul>
Image Credit: Gary A. Vasquez-Imagn Images

Fidelity NASDAQmposite Index Fund ETF-Tracking NASDAQmposite Index

ONEQ

The Buss Family Is Set To Sell The Los Angeles Lakers For $10 Billion, After Buying It For Just $68 Million—Here's Why The 15,284% Return Is Far From A Slam Dunk

Malibu Boats, the world's best-selling wakeboat brand, is thrilled to announce the continuation of its long-standing partnership with <a href="https://www.gm.com/">General Motors</a>, naming <a href="https://www.chevrolet.com/">Chevrolet</a> as the Official Vehicle Brand of Malibu Boats. This partnership reinforces Malibu Boats' commitment to excellence and innovation, extending their exclusive collaboration with <a href="https://poweredsolutions.gm.com/marine">GM Marine</a> for the vertical integration of the <a href="https://www.malibuboats.com/discover-malibu/malibu-monsoon-engines">Monsoon Line of engines</a> at the Malibu Boats Factory in Loudon, TN.

MBUU

Malibu Boats Extends Partnership With General Motors, Naming Chevrolet As Official Vehicle Brand And Continuing GM Marine Engine Integration

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.exxonmobil.com%2FCorporate%2Fdefault.aspx&amp;esheet=54279088&amp;newsitemid=20250618572574&amp;lan=en-US&amp;anchor=Exxon+Mobil+Corporation&amp;index=1&amp;md5=d66fd08baf0a7accfca3f32aca447a69">Exxon Mobil Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation to purchase up to 1 million shares of ExxonMobil common stock, which represents approximately 0.023 percent of the shares outstanding as of the June 9, 2025 offer date.
TRC's offer of $100 per ExxonMobil share is 4.1% below the closing price on June 6, 2025, on the New York Stock Exchange, the last trading day prior to opening of the offer. It is also more than 10% below its closing price yesterday.
ExxonMobil recommends that stockholders do not tender their shares in response to TRC's offer because the offer has a conditional market price for ExxonMobil's shares of $99.06 each and is subject to numerous other conditions. ExxonMobil is not affiliated or associated in any way with TRC, its mini-tender offer, or the offer documentation.
TRC has made similar mini-tender offers for shares of other companies. Mini-tender offers seek to acquire less than 5 percent of a company's shares outstanding, thereby avoiding many disclosure and procedural requirements of the U.S. Securities and Exchange Commission (SEC) that apply to offers for more than 5 percent of a company's shares outstanding. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under U.S. securities laws.

Management

Exxon Mobil Receives Unsolicited Mini-Tender Offer From TRC Capital To Purchase Up To 1M Shares At $100 Each; ExxonMobil Recommends That Stockholders Do Not Tender Their Shares In Response To TRC's Offer

UL Solutions' new battery containment enclosure and micromobility charging equipment certification programs help address growing concerns and incidents around lithium-ion battery safety risks and thermal runaway events.
UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>), a global leader in applied safety science, today announced its new testing and certification program for battery containment enclosures, including the battery charging or storage cabinets that are becoming more common on city sidewalks and in apartment buildings to address growing concerns around hazards of lithium-ion batteries for e-bikes.
Safety-certified battery containment enclosures are growing in popularity for use with e-bikes and other micromobility products, and are supported by fire departments, including the Fire Department of the City of New York (FDNY), for their ability to contain fire and other hazards associated with thermal runaway. UL Solutions also launched services for micromobility charging equipment that can further help mitigate safety risks.
Battery containment enclosures often resemble cabinets and are designed with safety features to contain battery thermal runaway fires and gases. They can be used to store and charge batteries, such as e-bike or power tool batteries, and help protect people around them if a thermal runaway event or battery fire occurs despite following proper battery maintenance and usage instructions from the manufacturer.

UL Solutions Launches Certification Programs For Battery Containment Enclosures And Micromobility Charging Equipment To Enhance Lithium-Ion Battery Safety And Prevent Thermal Runaway

Reliance Global Group, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) ("Reliance," "we," "us," "our" or the "Company"), today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,488,096 shares of its common stock (or pre-funded warrants in lieu thereof) and short-term warrants to purchase up to an aggregate of 2,976,192 shares of common stock at a purchase price of $1.68 per share (or per pre-funded warrant in lieu thereof) and accompanying short-term warrants in a private placement priced at-the-market under Nasdaq rules. The short-term warrants will be exercisable immediately upon issuance at an exercise price of $1.43 per share and will expire two years from the effective date of the Resale Registration Statement (as defined below). The offering is expected to close on or about June 20, 2025, subject to the satisfaction of customary closing conditions.&nbsp;
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.&nbsp;
The aggregate gross proceeds to the Company from the private placement is expected to be approximately $2.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $4.25 million. No assurance can be given that any of such short-term warrants will be exercised. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Offerings

RELI

Reliance Global Group Announces Definitive Agreements For Issuance Of 1.49M Shares And 2.98M Short-Term Warrants At $1.68 Per Share In Private Placement, Expected To Raise $2.5M Plus Potential $4.25M From Warrant Exercises

Jury concludes J&amp;J concealed the danger of its asbestos-laced talcum powder that caused woman's cancer
A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) talcum powder products.
The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer.
During the trial, the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdobslegal.com%2F&amp;esheet=54279382&amp;newsitemid=20250618099844&amp;lan=en-US&amp;anchor=Dean+Omar+Branham+Shirley&amp;index=1&amp;md5=d9fd59b911b8494899fa30004c35d027">Dean Omar Branham Shirley</a> legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson &amp; Johnson had internal knowledge of asbestos in its talc supply dating back decades yet continued to market the products as safe for daily use.
J&amp;J ceased production and sale of all products containing talc in the United States in 2020. Ms. Paluzzi, a lifelong user of the company's Baby Powder on herself and her children, was diagnosed with mesothelioma in 2021.

Legal

Johnson & Johnson Found Liable In Talc Cancer Case; Jury Awards $8M To Massachusetts Resident

Investar Holding Corporation (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISTR#NASDAQ">ISTR</a>), the holding company of Investar Bank, National Association (the "Bank"), declared a quarterly cash dividend of $0.11 per share to holders of the Company's common stock. The dividend is payable on July 31, 2025 to shareholders of record as of June 30, 2025. This represents a 5% increase in the dividend per share compared to the prior quarter and is the 47th quarterly dividend paid by the Company, which follows an uninterrupted 11 quarterly cash dividends paid by the Bank.

Dividends

ISTR

Investar Holding Corp Increases Quarterly Cash Dividend From $0.10 To $0.11 Per Share

General Dynamics Electric Boat, a business unit of General Dynamics (NYSE:&nbsp;GD), announced today it has been awarded a $987 million contract modification to a previously awarded contract supporting submarine production. This modification is for additional Component Development, Class Lead Yard Support (CLYS), and Submarine Industrial Base (SIB) supplier development enhancements, as detailed in the U.S. Department of Defense <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4452671-1&amp;h=3622296494&amp;u=https%3A%2F%2Fwww.defense.gov%2FNews%2FContracts%2FContract%2FArticle%2F4221136%2F&amp;a=contract+award">contract award</a>.

Contracts

General Dynamics Electric Boat Secures $987M Contract Modification To Boost Submarine Production And Supplier Development

Franco-Nevada Corporation ("Franco-Nevada") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FNV#TSX">FNV</a>) (NYSE:&nbsp;FNV) provides an update regarding its arbitration proceeding related to the Cobre Panama mine. Following engagement with the Government of Panama's legal counsel, Franco-Nevada has agreed today to suspend its arbitration proceeding. Franco-Nevada had previously filed a request for arbitration under the Canada-Panama Free Trade Agreement to the International Centre for Settlement of Investment Disputes on June 27, 2024.

TSX:FNV

Franco-Nevada Suspends Arbitration Against Panama Over Cobre Panama Mine Following Government Engagement

No Shareholder Action Required at This Time
GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) (the "Company"), a leading North American specialty building products distributor, confirmed that it has received an unsolicited proposal from QXO, Inc. ("QXO") to acquire all outstanding shares of GMS for $95.20 per share in cash.
Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the GMS Board of Directors will carefully review and evaluate the unsolicited proposal to determine the course of action that it believes is in the best interests of the Company and all GMS shareholders.
GMS does not intend to comment further on QXO's unsolicited proposal until the Board has completed its review. GMS shareholders do not need to take any action at this time.

GMS Confirms Receipt Of $95.20 Per Share Unsolicited Buyout Proposal From QXO

Annovis Bio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards relating to minimum market capitalization and stockholders' equity.
In the Acceptance Letter, the NYSE granted the Company an 18-month period from the Company's receipt of the NYSE's Notice of Noncompliance dated March 26, 2025 (the "Plan Period") to regain compliance with the continued listing standards. As part of the Plan, the Company is required to provide the NYSE quarterly updates regarding its progress towards the goals and initiatives in the Plan.
The Company expects its stock will continue to be listed on the NYSE during the Plan Period, subject to the Company adherence to the Plan and compliance with other applicable NYSE continued listing standards. The Company's receipt of such notification from the NYSE does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission.

ANVS

Annovis Bio Announces It Received NYSE Acceptance Letter Granting The Co 18-Month Period To Maintain Listing

More than 2 million acres of public land across 11 states could go up for sale under the current version of the <a href="https://www.benzinga.com/news/politics/25/06/45967060/senate-republicans-unveil-trump-tax-and-health-plan-with-5-trillion-debt-ceiling-hike-tighter-medicaid-rules-in-the-big-beautiful-bill">Republican budget bill</a>. The proposal has drawn criticism from conservation groups, hunting organizations, local officials and some conservative leaders, too.
What Happened: Sen. Mike Lee (R-Utah), who leads the Senate Energy and Natural Resources Committee, included a provision in the draft budget bill that would authorize the sale of federal lands. According <a href="https://thehill.com/homenews/nexstar_media_wire/5358034-proposed-sale-of-millions-of-acres-of-public-land-under-gop-budget-bill-prompts-backlash/">to</a> The Hill, the proposal reflects a long-standing goal among Western conservatives to institute more local control over federal lands.
Though national parks and designated wilderness areas would be excluded, Lee said the targeted parcels are "isolated" and more suited for housing and infrastructure. "Washington has proven time and again it can't manage this land. This bill puts it in better hands," Lee argued in a video posted by his office.
Lee has faced opposition from within his party, and a similar land sale provision was already rejected in the House.
Rep. Ryan Zinke&nbsp;(R-Mont.)&nbsp;spearheaded the effort to remove the land sale provision from the House version, declaring himself a "hard no" on such proposals.
See Also: <a href="https://www.benzinga.com/markets/treasuries/25/06/46012056/peter-schiff-predicts-worse-financial-crisis-than-2008-as-fed-holds-rates-the-solution-involves-much-higher-interest-rates-as-years-of-easy-money-trigger-stagflation-and-investor-exodus">Peter Schiff Predicts &#8216;Worse Financial Crisis Than 2008&#8217; As Fed Holds Rates: &#8216;The Solution Involves Much Higher Interest Rates&#8217; As Years of Easy Money Trigger Stagflation And Investor Exodus</a>
Why It Matters: As per The Wilderness Society's estimates, over 250 million acres could be vulnerable under this policy. Michael Carroll of The Wilderness Society called the move "a betrayal of future generations." Sen. Martin Heinrich (D-NM), the Senate energy committee's ranking Democrat, warned that the outcome would be the loss of public access to cherished outdoor spaces, with negligible benefit to the housing supply.
Environmental advocate Benji Backer called the proposal a "loser issue" in a social media post, adding, "I've never seen so many conservatives AND liberals stand together as I've seen in opposition to this proposed mass sale of public lands."
A recent YouGov poll showed that 71% of Americans do not agree with such land sales, including majorities of both Trump and Harris voters.
In March, the Trump administration reportedly set up a task force to identify suitable sections from 650 million acres of federal land to develop <a href="https://www.benzinga.com/news/25/03/44376829/trump-administration-plans-to-construct-nearly-4-million-affordable-homes-on-federal-land">new housing to address the nationwide shortage.</a> In the same month, President Donald Trump also signed an executive order to expand logging on <a href="https://www.benzinga.com/news/25/03/44221143/horrific-move-to-loot-our-public-lands-trump-signs-executive-order-to-clear-cut-280m-acres-of-national-fores">280 million acres of federal land</a>, bypassing environmental safeguards and aiming to boost timber sales.
Read Next
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk's Brain Chip</a></li>
</ul>
Photo courtesy: rafapress / Shutterstock.com

Politics

GOP Budget Bill Plans To Sell Over 2 Million Acres Of Public Land Across 11 States, Faces Pushback From Lawmakers And Conservationists

Empire Co (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EMP#TSX">EMP</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.71 by 4.23 percent. This is a 17.46 percent increase over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $7.64 billion which missed the analyst consensus estimate of $7.66 billion by 0.30 percent. This is a 3.04 percent increase over sales of $7.41 billion the same period last year.

TSX:EMP

TSX:EMP.A

Empire Co Q4 EPS $0.74 Beats $0.71 Estimate, Sales $7.64B Miss $7.66B Estimate

Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) announced today that the company was awarded a $137 million ceiling value contract by the Defense Threat Reduction Agency (DTRA) for cyber operations. The single award was issued under the Assessment, Exercise, Modeling and Simulation, and Support (AEMSS) indefinite-delivery, indefinite-quantity (IDIQ) multiple award task order contract (MATOC) with a one-year base period of performance and four one-year option periods plus one six-month option period and is new work for the company. Parsons will provide specialized cyber operations capabilities including cyber assessments and subject matter experts supporting cyber operations, development, analysis, and research.

Parsons Secures $137M Ceiling Value Contract By The Defense Threat Reduction Agency For Cyber Operations

Neuralink, Elon Musk's BCI or Brain-Chip Interface company, has added a BCI implant on a sixth individual.
What Happened: "Absolutely amazing what I can do already in under a week with Neuralink!" said Rob Grenier in a post on social media platform X on Wednesday.
The post showcased Grenier playing a videogame on a computer as well as controlling the cursor on a computer screen with his thoughts through the help of the implant.
Grenier was involved in a vehicular accident in December 2022, which left him quadraplegic from the neck down.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Absolutely amazing what I can do already in under a week with Neuralink! I can&#39;t thank the Neuralink team, the doctors, the surgeons and all of my family and friends support. It may only look like I&#39;m doing a couple games but it&#39;s been under a week and I&#39;m already shocked! <a href="https://t.co/5LEZzwumbx">pic.twitter.com/5LEZzwumbx</a>
&mdash; Rob Greiner (@greiner_ro52817) <a href="https://twitter.com/greiner_ro52817/status/1935141580220117225?ref_src=twsrc%5Etfw">June 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The news comes in as Neuralink raised over $650 million in Series E funding, with Cathie Wood's investment firm ARK Invest among the company's key investors. The company currently has a <a href="https://www.benzinga.com/general/health-care/25/05/45634160/elon-musks-neuralink-hits-9-billion-valuation-with-new-funding">valuation of $9 billion</a>.
The company also partnered with the <a href="https://www.benzinga.com/25/05/45538889/elon-musk-shares-major-neuralink-update-at-qatar-economic-forum">UAE's Cleveland Clinic</a>, where it will conduct the first human trial of its Blindsight chip in 2026. Musk had previously touted the <a href="https://www.benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes">Blindsight chipset's potential</a>.
"With Neuralink interfacing directly to the visual cortex, even those who are completely blind will be able to see again," he had said.
Neuralink also used its BCI implant on a <a href="https://www.benzinga.com/25/04/45032464/man-suffering-from-als-becomes-the-first-ever-non-verbal-recipient-elon-musks-neuralink-brain-implant">man battling ALS</a>, who became the third recipient of the company's chip, as well as the first non-verbal recipient of the implant.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk's Brain Chip</a></li>
</ul>
Photo courtesy: rafapress / Shutterstock.com

Tech

Elon Musk's Neuralink Implants Brain Chip In 6th Patient, Enables Paralyzed Man To Move Cursor, Play Game With His Mind

<ul>
<li>Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trials</li>
<li>Real-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared</li>
<li>Booth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes</li>
</ul>
Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) (Insulet or the Company), the global leader in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.myomnipod.com%2F&amp;esheet=54278472&amp;newsitemid=20250619043429&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=f48e637a11bb31e5c4a7e3ac755aa0d1">tubeless insulin pump</a> technology with its Omnipod&#xAE; brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, Illinois.

PODD

Insulet To Showcase SECURE-T2D, RADIANT Clinical Trial Results And Real-World Omnipod 5 Data At ADA 2025

Press Releases

NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

NeuroOne® OneRF® Technology Success Story Featured on Fox News

NeuroOne® Issues Letter to Shareholders

NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time

NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025

NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

HeartBeam

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS

Femasys

Hyperfine

SeaStar Medical Holding Corporation - Common Stock

SeaStar Medical Holding

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

Iridex

Know Labs

Milestone Scientific

Modular Medical

Neuraxis

Nexalin Technology

PAVmed

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Trinity Biotech plc - American Depositary Shares

Trinity Biotech

Vivani Medical

Beyond Air

Zynex

Ladenburg Thalmann

Alliance Global Partners

Screenshot 2024-05-03 at 5.56.54 PM

Interview

NeuroOne – The Medical Device Company That Has Created A Product That Could Monitor And Treat At The Same Time

Screenshot 2024-03-27 at 5.33.58 PM

NeuroOnes&#39;s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Screenshot 2024-03-07 at 8.32.36 PM

Health Care

Movers & Shakers

ATITK

NeuroOne Medical Technologies&#39; (NASDAQ: NMTC) Innovative Brain Monitoring Tech Developing And Commercializing Electrodes To Provide Insights To Help Physicians Treat Neurological Disorders Like Epilepsy

금요일(4일) 아침 미국 지수 선물이 하락세를 보이는 가운데, 오늘 투자자의 관심을 끌 수 있는 주식은 다음과 같다.
<ul>
<li>아메리칸 셰어드 호스피털 서비스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>): 금요일 개장 전 실적을 발표할 예정이며, 매출 770만 달러 및 주당순이익 1센트가 예상된다. 주가는 목요일 애프터마켓에서 0.3% 상승하여 2.97달러에 거래되었다.</li>
<li>게스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>): 4분기에 긍정적인 실적을 발표하고 알베르토 토니를 CFO로 임명했다. 2026회계연도 매출이 미국 달러로 3.9%~6.2% 증가하고 조정 주당순이익이1.32~1.76달러가 될 것으로 예상한다고 밝혔다. 주가는 목요일 애프터마켓에서 2.4% 하락하여 9.80달러에 거래되었다.</li>
<li>뉴로원 메디컬 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>): 보통주 공개 발행을 발표했다. 주가는 목요일 애프터마켓에서 36.1% 하락하여 0.5499달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>시뮬레이션스 플러스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>): 2분기에 예상보다 강한 실적을 발표하고 2025회계연도 수익 전망을 긍정적으로 제시했다. 주가는 목요일 애프터마켓에서 2.5% 상승하여 24.41달러에 거래되었다.</li>
<li>상가모 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>): 제약 대기업 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 새로운 계약을 발표하며, 상가모의 독창적인 신경영향 아데노 바이러스(AAV) 캡시드인 STAC-BBB에 대한 전세계 독점 라이센스를 부여받았다. 주가는 목요일 애프터마켓에서 47.7% 급등하여 0.9193달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

NeuroOne Medical Tech

뉴스

에 대한 최신 뉴스 NeuroOne Medical Tech (NASDAQ:NMTC) 주식

금요일, 4월 04, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌